High frequency of BRAF mutations in nevi
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
To evaluate the timing of mutations in BRAF (v-raf murine sarcoma viral oncogene homolog B1) during melanocytic neoplasia, we carried out mutation analysis on microdissected melanoma and nevi samples. We observed mutations resulting in the V599E amino-acid substitution in 41 of 60 (68%) melanoma metastases, 4 of 5 (80%) primary melanomas and, unexpectedly, in 63 of 77 (82%) nevi. These data suggest that mutational activation of the RAS/RAF/MAPK pathway in nevi is a critical step in the initiation of melanocytic neoplasia but alone is insufficient for melanoma tumorigenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, the BRAF oncogenic mutation found in more than half of all malignant cutaneous melanomas is commonly found also in non-malignant nevi, where it causes oncogene-induced senescence exemplified by high levels of CDKN2A and SA-β-gal expression225–227.”
From SenNet recommendations for detecting senescent cells in different tissues (2024) · cites this paper as [226]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Tissue microarrays for high-throughput molecular profiling of tumor specimens
Kononen, J., Bubendorf, L., Kallionimeni, A., Bärlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., & Kallionimeni, O.-P. (1998) · Nature Medicine · doi:10.1038/nm0798-844 · Cited by 4,099
Busca, R. (2000) · The EMBO Journal · doi:10.1093/emboj/19.12.2900 · Cited by 326
The Regulation of Normal Melanocyte Proliferation
Halaban, R. (2000) · Pigment Cell Research · doi:10.1034/j.1600-0749.2000.130103.x · Cited by 179
Research works printed but not linked: 2
- Armstrong, B.K. & English, D.R. in Cancer Epidemiology and Prevention (Oxford University Press, New York, 1996).
- Elder, D.E. & Murphy, G.F. in Atlas of Tumor Pathology: Melanocytic Tumors of the Skin 5–101 (Armed Forces Insititute of Pathology, Washington, DC, 1991).
Cited by
Items 201–300 of 1,001
The Raf Inhibitor BAY 43-9006 (Sorafenib) Induces Caspase-Independent Apoptosis in Melanoma Cells
Panka, D. J., Wang, W., Atkins, M. B., & Mier, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-0808 · Cited by 167
“However, it has been observed in f80% of benign nevi (7), indicating that it is only one of several factors contributing to melanoma development.”
BackgroundRetractedChinta, S. J., Lieu, C. A., DeMaria, M., Laberge, R. ‐., Campisi, J., & Andersen, J. K. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12029 · Cited by 165
“We and others recently demonstrated that a genetically induced tissue-specific deficiency in the mitochondrial antioxidant enzyme superoxide dismutase induces cellular senescence and ageing phenotypes in the epidermis of mice [27, 34].”
Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice
Goel, V. K., Ibrahim, N., Jiang, G., Singhal, M., Fee, S., Flotte, T., Westmoreland, S., Haluska, F. S., Hinds, P. W., & Haluska, F. G. (2009) · Oncogene · doi:10.1038/onc.2009.95 · Cited by 165
“BRAF mutation is not sufficient to induce malignancy: it has been shown that up to 80% of benign nevi carry the same mutation in BRAF as is observed in melanoma (Pollock et al., 2003).”
Ikenoue, T., Hikiba, Y., Kanai, F., Tanaka, Y., Imamura, J., Imamura, T., Ohta, M., Ijichi, H., Tateishi, K., Kawakami, T., et al. (2003) · PubMed · Cited by 164
Loughrey, M. B., Waring, P. M., Tan, A., Trivett, M., Kovalenko, S., Beshay, V., Young, M.-A., McArthur, G., Boussioutas, A., & Dobrovic, A. (2007) · Familial Cancer · doi:10.1007/s10689-007-9124-1 · Cited by 165
“[38] and the BRAF exon 15 sequencing primers”
BackgroundCoupling Sensitive Nucleic Acid Amplification with Commercial Pregnancy Test Strips
Du, Y., Pothukuchy, A., Gollihar, J. D., Nourani, A., Li, B., & Ellington, A. D. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201609108 · Cited by 163
Inamura, K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041259 · Cited by 160
“Although nevi frequently harbor the oncogenic BRAFV600E mutation [107], the initial step of nevus growth is typically followed by growth arrest from oncogene-induced senescence that blocks BRAFV600E-mediated oncogenic signaling.”
BackgroundThe genome and epigenome of malignant melanoma
DAHL, C., & GULDBERG, P. (2007) · APMIS · doi:10.1111/j.1600-0463.2007.apm_855.xml.x · Cited by 162
“Interestingly, BRAFV600E has been found at very high frequencies (up to 80%) in benign and dysplastic nevi, suggesting that it represents one of the first events in melanocytic neoplasia (26).”
BackgroundValidating cancer drug targets
Benson, J. D., Chen, Y.-N. P., Cornell-Kennon, S. A., Dorsch, M., Kim, S., Leszczyniecka, M., Sellers, W. R., & Lengauer, C. (2006) · Nature · doi:10.1038/nature04873 · Cited by 161
“The presence of these mutations in both precancerous lesions and metastatic melanoma suggests that this genetic change might be an early event in tumorigenesi”
Backgroundvan Dijk, M. C. R. F., Bernsen, M. R., & Ruiter, D. J. (2005) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000157749.18591.9e · Cited by 162
Genetic alterations of PTEN in human melanoma
Aguissa-Touré, A.-H., & Li, G. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0878-0 · Cited by 160
Somatic driver mutations in melanoma
Reddy, B. Y., Miller, D. M., & Tsao, H. (2017) · Cancer · doi:10.1002/cncr.30593 · Cited by 160
“It is worth noting that approximately 80% of benign nevi harbor BRAF V600E mutations; hence, BRAF mutations alone are not sufficient to drive tumorigenesis.(24) BRAF mutations are typically associated with melanomas identified in younger patients and from sites with intermittent sun exposure.”
BackgroundSmalley, K. S. M., Brafford, P., Haass, N. K., Brandner, J. M., Brown, E., & Herlyn, M. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62370-x · Cited by 163
“In particular the high incidence of BRAF V600E mutations in benign nevi is thought to contribute to the later oncogenic behavior of VGP and metastatic melanomas.(36) ZO-1 is also found in normal human skin where it is expressed primarily in the stratum granulosum, the transitional layer of the epidermis, and weakly in…”
BackgroundClinical, Histopathologic, and Genomic Features of Spitz Tumors With ALK Fusions
Yeh, I., de la Fouchardiere, A., Pissaloux, D., Mully, T. W., Garrido, M. C., Vemula, S. S., Busam, K. J., LeBoit, P. E., McCalmont, T. H., & Bastian, B. C. (2015) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000387 · Cited by 158
KRAS and BRAF: drug targets and predictive biomarkers
Vakiani, E., & Solit, D. B. (2011) · The Journal of Pathology · doi:10.1002/path.2796 · Cited by 162
Current understanding and management of pulmonary Langerhans cell histiocytosis
Vassallo, R., Harari, S. A., & Tazi, A. (2017) · Thorax · doi:10.1136/thoraxjnl-2017-210125 · Cited by 158
“30 Functionally, this BRAF V600E mutation results in a modified kinase domain that is associated with constitutive activation of the mitogen-activated protein kinase (MAPK) pathway which plays a key role in cell differentiation and survival (figure 1).”
Background3D genomic mapping reveals multifocality of human pancreatic precancers
Braxton, A. M., Kiemen, A. L., Grahn, M. P., Forjaz, A., Parksong, J., Babu, J. M., Lai, J., Zheng, L., Niknafs, N., Jiang, L., et al. (2024) · Nature · doi:10.1038/s41586-024-07359-3 · Cited by 180
NTRK3 kinase fusions in Spitz tumours
Yeh, I., Tee, M. K., Botton, T., Shain, A. H., Sparatta, A. J., Gagnon, A., Vemula, S. S., Garrido, M. C., Nakamaru, K., Isoyama, T., et al. (2016) · The Journal of Pathology · doi:10.1002/path.4775 · Cited by 164
Clinicopathological relevance of BRAF mutations in human cancer
Pakneshan, S., Salajegheh, A., Anthony Smith, R., & King-Yin Lam, A. (2013) · Pathology · doi:10.1097/pat.0b013e328360b61d · Cited by 156
Gray‐Schopfer, V. C., Dias, S. D. R., & Marais, R. (2005) · Cancer and Metastasis Reviews · doi:10.1007/s10555-005-5865-1 · Cited by 181
“Finally, BRAF mutations are found in congenital nevi [58,84], which arise prior to UV exposure and B-RAF mutations of the types found in melanoma are also found in thyroid, ovarian and colorectal cancers (reviewed in [43]) where UV light clearly cannot be responsible.”
BackgroundMethodSatoh, T., Smith, A., Sarde, A., Lu, H.-C., Mian, S., Trouillet, C., Mufti, G., Emile, J.-F., Fraternali, F., Donadieu, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033891 · Cited by 157
“In human, somatic B-RAF mutation have been found in a number of benign and malignant tumors including non-malignant naevi [25], melanoma [26], colon and thyroid tumors [21,22,24,26].”
BackgroundBRAF as a potential therapeutic target in melanoma and other malignancies
Tuveson, D. A., Weber, B. L., & Herlyn, M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00189-2 · Cited by 157
“Perhaps even more unexpected was the demonstration that the BRAFV599E allele could be detected in as many as 80% of benign nevi, suggesting a role for oncogenic BRAF in nevus formation and melanoma initiation (Pollock et al., 2003).”
BackgroundWeiss, M. B., Abel, E. V., Mayberry, M. M., Basile, K. J., Berger, A. C., & Aplin, A. E. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1033 · Cited by 155
“B-RAF mutations are common in pre-neoplastic nevi and, therefore, are considered by many to represent an initiation step in melanoma progression (43).”
BackgroundMAP kinase signaling and inhibition in melanoma
Sullivan, R. J., & Flaherty, K. T. (2012) · Oncogene · doi:10.1038/onc.2012.345 · Cited by 173
Overexpression of Collagenase 1 (MMP-1) Is Mediated by the ERK Pathway in Invasive Melanoma Cells
Huntington, J. T., Shields, J. M., Der, C. J., Wyatt, C. A., Benbow, U., Slingluff, C. L., & Brinckerhoff, C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405102200 · Cited by 161
Murphy, D. A., Makonnen, S., Lassoued, W., Feldman, M. D., Carter, C., & Lee, W. M. F. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.050711 · Cited by 154
Fagin, J. A. (2004) · Journal of Endocrinology · doi:10.1677/joe.1.05895 · Cited by 155
“BRAF somatic mutations were recently reported in a high proportion of benign nevi (Pollock et al. 2003) and malignant melanomas (Davies et al.”
BackgroundB-Raf and Raf-1 Are Regulated by Distinct Autoregulatory Mechanisms
Tran, N. H., Wu, X., & Frost, J. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501185200 · Cited by 154
Melanoma Epidemiology and Prevention
Berwick, M., Buller, D. B., Cust, A. E., Gallagher, R. P., Lee, T. K., Meyskens, F. L., Pandey, S., Thomas, N. E., Veierød, M. B., & Ward, S. V. (2015) · Cancer treatment and research · doi:10.1007/978-3-319-22539-5_2 · Cited by 169
Lin, K., Baritaki, S., Militello, L., Malaponte, G., Bevelacqua, Y., & Bonavida, B. (2010) · Genes & Cancer · doi:10.1177/1947601910373795 · Cited by 164
“Observations show that 82% of benign nevi have high frequencies of B-RAF mutations relative to frequencies seen in RGP tumors.(21) This disparity in the frequency of activating B-RAF mutations between benign nevi and RGP tumors implicates that B-RAF mutations alone cannot induce melanoma but must cooperate with other…”
BackgroundMolecular diagnostics in melanoma
Carlson, J. A., Ross, J. S., Slominski, A. T., Linette, G. P., Mysliborski, J., Hill, J., & Mihm, M. C. (2005) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2004.08.034 · Cited by 164
The roles of microphthalmia-associated transcription factor and pigmentation in melanoma
Hsiao, J. J., & Fisher, D. E. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.07.019 · Cited by 148
Bhatt, K. V., Spofford, L. S., Aram, G., McMullen, M. E., Pumiglia, K. M., & Aplin, A. E. (2005) · Oncogene · doi:10.1038/sj.onc.1208544 · Cited by 153
Genetic risk factors for melanoma
Meyle, K. D., & Guldberg, P. (2009) · Human Genetics · doi:10.1007/s00439-009-0715-9 · Cited by 178
“Notably, this mutation has also been found in up to 80% of benign and dysplastic nevi (Pollock et al. 2003).”
BackgroundThe Conundrum of Genetic “Drivers” in Benign Conditions
Kato, S., Lippman, S. M., Flaherty, K. T., & Kurzrock, R. (2016) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw036 · Cited by 146
Halait, H., DeMartin, K., Shah, S., Soviero, S., Langland, R., Cheng, S., Hillman, G. R., Wu, L., & Lawrence, H. J. (2012) · Diagnostic Molecular Pathology · doi:10.1097/pdm.0b013e31823b216f · Cited by 145
“The analytical sensitivity based on hit rates (Table 1) was assessed using DNA blends from melanoma cell lines, DNA blends from FFPET melanoma specimens, and individual FFPET tumor specimens with low levels of BRAF mutant alleles (as determined by 454 sequencing).(4) A correct mutation call rate of >96% was obtained a…”
BackgroundMethodModelling cancer in human skin tissue
Khavari, P. A. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1838 · Cited by 175
“Consistent with the first possibility are the observations that BRAF mutations are more common in benign naevi than in metastatic malignant melanom”
BackgroundCombined activation of MAP kinase pathway and β-catenin signaling cause deep penetrating nevi
Yeh, I., Lang, U. E., Durieux, E., Tee, M. K., Jorapur, A., Shain, A. H., Haddad, V., Pissaloux, D., Chen, X., Cerroni, L., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00758-3 · Cited by 148
Carragher, L. A. S., Snell, K. R., Giblett, S. M., Aldridge, V. S. S., Patel, B., Cook, S. J., Winton, D. J., Marais, R., & Pritchard, C. A. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000099 · Cited by 144
“It is detected in up to 80% of human nevi that remain unchanged for many years (Pollock et al, 2003) and, when over-expressed in human melanocytes in vitro (Michaloglou et al, 2005) and zebrafish melanocytes in vivo (Patton et al, 2005), V600EBraf can induce classical hallmarks of oncogene-induced…”
Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy
Botton, T., Yeh, I., Nelson, T. A., Vemula, S. S., Sparatta, A. J., Garrido, M. C., Allégra, M., Rocchi, S., Bahadoran, P., McCalmont, T. H., et al. (2013) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12148 · Cited by 147
“The majority of melanocytic neoplasms harbor activating point mutations in BRAF (Davies et al., 2002; Pollock et al., 2003), NRAS (Padua et al.”
BackgroundEisenmann, K. M., VanBrocklin, M. W., Staffend, N. A., Kitchen, S. M., & Koo, H.-M. (2003) · PubMed · Cited by 168
mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation
Damsky, W., Micevic, G., Meeth, K., Muthusamy, V., Curley, D. P., Santhanakrishnan, M., Erdelyi, I., Platt, J. T., Huang, L., Theodosakis, N., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.014 · Cited by 142
“About 80% of nevi have BRAFV600E mutations (Pollock et al., 2003).”
BackgroundMolecular Pathogenesis of Ovarian Borderline Tumors: New Insights and Old Challenges
Shih, I.-M., & Kurman, R. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0755 · Cited by 142
Malignant Melanoma in the 21st Century: The Emerging Molecular Landscape
Sekulic, A., Haluska, P., Miller, A. J., De Lamo, J. G., Ejadi, S., Pulido, J. S., Salomao, D. R., Thorland, E. C., Vile, R. G., Swanson, D. L., et al. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.7.825 · Cited by 148
High BRAF mutation frequency does not characterize all melanocytic tumor types
Saldanha, G., Purnell, D., Fletcher, A., Potter, L., Gillies, A., & Pringle, J. H. (2004) · International Journal of Cancer · doi:10.1002/ijc.20325 · Cited by 141
BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs
Wong, C. W., Fan, Y. S., Chan, T. L., Chan, A. S. W., Ho, L. C., Ma, T. K. F., Yuen, S. T., & Leung, S. Y. (2005) · Journal of Clinical Pathology · doi:10.1136/jcp.2004.022509 · Cited by 141
Kono, M., Dunn, I. S., Durda, P. J., Butera, D., Rose, L. B., Haggerty, T. J., Benson, E. M., & Kurnick, J. T. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0077 · Cited by 141
“Because activating mutations in NRAS might be an alternate source of high steady-state pERK levels, we checked the cell lines for the Q61R/K/L mutations known to activate RAS proteins constitutively (20, 31-35).”
BackgroundUribe, P., Wistuba, I. I., & González, S. (2003) · American Journal of Dermatopathology · doi:10.1097/00000372-200310000-00001 · Cited by 142
“While this article was in preparation, a study reporting BRAF mutations at codon 599 in benign and atypical nevi of skin was published.(22) The authors of that report found mutations in 53 of 65 (82%) benign and 4 of 5 (80%) atypical nevi.”
BackgroundHudlebusch, H. R., Santoni‐Rugiu, E., Simon, R., Ralfkiaer, E. M., Holten‐Rossing, H., Johansen, J. V., Jørgensen, M., Sauter, G., & Helin, K. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1302 · Cited by 139
“High expression of B-RAF in benign nevus mostly leads to senescence whereas in melanoma, high B-RAF expression leads to a poor outcome (34-36).”
BackgroundAnderson, S., Bloom, K. J., Vallera, D. U., Rueschoff, J., Meldrum, C. J., Schilling, R., Kovach, B., Lee, J. R.-J., Ochoa, P., Langland, R., et al. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2011-0505-oa · Cited by 149
“In melanoma, the development of BRAF mutations appears to be an early event, occurring in many benign nevi.(8) BRAF mutations are more prevalent in melanomas occurring in younger patients, and in areas of non– chronically sun-exposed areas of the body (eg, trunk, limbs).”
BackgroundBlue Nevi and Variants: An Update
Zembowicz, A., & Phadke, P. A. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2009-0733-ra.1 · Cited by 138
The genomic landscapes of individual melanocytes from human skin
Tang, J., Fewings, E., Chang, D., Zeng, H., Liu, S., Jorapur, A., Belote, R. L., McNeal, A. S., Tan, T. M., Yeh, I., et al. (2020) · Nature · doi:10.1038/s41586-020-2785-8 · Cited by 137
Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas
REIFENBERGER, J., Knobbe-Thomsen, C. B., Sterzinger, A. A., Blaschke, B., Schulte, K. W., Ruzicka, T., & Reifenberger, G. (2004) · International Journal of Cancer · doi:10.1002/ijc.11722 · Cited by 146
Understanding Melanoma Signaling Networks as the Basis for Molecular Targeted Therapy
Smalley, K. S. M. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.177 · Cited by 158
Molecular Pathogenesis of Cutaneous Melanocytic Neoplasms
Ibrahim, N., & Haluska, F. G. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.3.121806.151541 · Cited by 138
Ryder, M., Gild, M., Hohl, T. M., Pamer, E., Knauf, J., Ghossein, R., Joyce, J. A., & Fagin, J. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054302 · Cited by 138
“Oncogenic mutations of BRAF are the most common genetic events in melanomas [11] and papillary thyroid cancers (PTC) [12,13], and are thought to be involved in early stages of tumor development, as they are present in benign nevi [14] and micropapillary thyroid cancers [15], respectively.”
BackgroundNAKATO, N., Takata, M., Takayanagi, S., Takashima, S., Lin, J., Murata, H., Fujimoto, A., Hatta, N., & Saida, T. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700366 · Cited by 151
“Recently, a high frequency of oncogenic BRAF (V-raf murine sarcoma virus oncogene homolog B1) mutations at a single site in the kinase domain of the exon 15 has been reported in melanomas and melanocytic nevi, suggesting that the mutational activation of the RAS/RAF/MEK/ERK pathway is a critical step in the developmen…”
BackgroundResultInfluentialBRAF and KRAS mutations in stomach cancer
Lee, S. H., Lee, J. W., Soung, Y. H., Kim, H. S., Park, W. S., Kim, S. Y., Lee, J., Park, J. Y., Cho, Y. G., Kim, C. J., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206749 · Cited by 135
Lack of BRAF Mutation in Primary Uveal Melanoma
Cohen, Y., Goldenberg‐Cohen, N., Parrella, P., Chowers, I., Merbs, S. L., Pe’er, J., & Sidransky, D. (2003) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.02-1329 · Cited by 135
“This hot spot was chosen because the reported BRAFactivating mutations in cutaneous nevi and cutaneous melanoma occur almost exclusively in this position.(15,19)”
BackgroundMelanoma: Molecular pathogenesis and emerging target therapies (Review)
Libra (2009) · International Journal of Oncology · doi:10.3892/ijo_00000277 · Cited by 136
“Several studies have shown the presence of the same mutations also in a high percentage of benign nevi, suggesting activation of the MAPK pathway is a necessary event for melanoma development, but it is not sufficient for malignant transformation (51,52).”
Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines
Bloethner, S., Chen, B., Hemminki, K., Müller-Berghaus, J., Ugurel, S., Schadendorf, D., & Kumar, R. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi066 · Cited by 138
BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model
Perna, D., Karreth, F. A., Rust, A. G., Perez-Mancera, P. A., Rashid, M., Iorio, F., Alifrangis, C., Arends, M. J., Bosenberg, M. W., Bollag, G., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1418163112 · Cited by 135
“These results are in keeping with the presence of BRAF mutations in up to 85% of melanocytic nevi in humans (24, 25).”
ResultOncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma
Bauer, J. M., Kilic, E., Vaarwater, J., Bastian, B. C., Garbe, C., & de Klein, A. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605226 · Cited by 133
“…4 August 2009 & 2009 Cancer Research UK Keywords: uveal melanoma; survival; oncogenic mutation Cutaneous melanocytic nevi and melanomas show frequent oncogenic mutations in BRAF and NRAS, and consequent constitutive activation of the MAP-kinase pathway (Davies et al, 2002; Pollock et al, 2003).”
BackgroundMolecular drivers of cellular metabolic reprogramming in melanoma
Abildgaard, C., & Guldberg, P. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.12.007 · Cited by 154
Mar, V., Wong, S. Q., Li, J., Scolyer, R. A., McLean, C., Papenfuss, A. T., Tothill, R. W., Kakavand, H., Mann, G. J., Thompson, J. F., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0398 · Cited by 152
“BRAF mutations are known to occur in melanocytic nevi (39) and in situ melanomas.”
BackgroundTargets of Raf in tumorigenesis
Niault, T. S., & Baccarini, M. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp337 · Cited by 132
GNAQ and GNA11 mutations in uveal melanoma
Shoushtari, A. N., & Carvajal, R. D. (2014) · Melanoma Research · doi:10.1097/cmr.0000000000000121 · Cited by 144
Melanoma: From Melanocyte to Genetic Alterations and Clinical Options
Bertolotto, C. (2013) · Scientifica · doi:10.1155/2013/635203 · Cited by 190
“In aggregates, a high frequency of activating BRAF mutations (80%) was identified in nevi, indicating that activating BRAF mutations occurs early during melanoma progression [122], an idea supported by recent findings showing that the BRAFV600E mutation was present in the majority of, if not all of, melanocytes in the…”
ResultKRAS, NRAS and BRAF mutations in colorectal cancer and melanoma
Cicenas, J., Tamošaitis, L., Kvederavičiūtė, K., Tarvydas, R., Staniute, G., Kalyan, K. P., Meškinytė-Kaušilienė, E., Stankevičius, V., & Valius, M. (2017) · Medical Oncology · doi:10.1007/s12032-016-0879-9 · Cited by 159
Mutations of the BRAF gene in squamous cell carcinoma of the head and neck
Weber, A., Langhanki, L., Sommerer, F., Markwarth, A., Wittekind, C., & Tannapfel, A. (2003) · Oncogene · doi:10.1038/sj.onc.1206705 · Cited by 131
Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets
Knauf, J. A., & Fagin, J. A. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.01.013 · Cited by 143
“of PTC and melanomas, since they are found in microPTC [8] and the majority of benign nevi [9], which are thought to be precursors of PTCs and melanomas, respectively.”
BackgroundCutaneous Melanoma Subtypes Show Different BRAF and NRAS Mutation Frequencies
Saldanha, G. S., Potter, L., DaForno, P., & Pringle, J. H. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2447 · Cited by 141
Chen, J.-H., Faquin, W. C., Lloyd, R. V., & Nosé, V. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.2 · Cited by 139
The RalGEF-Ral Effector Signaling Network: The Road Less Traveled for Anti-Ras Drug Discovery
Neel, N. F., Martin, T. D., Stratford, J. K., Zand, T. P., Reiner, D. J., & Der, C. J. (2011) · Genes & Cancer · doi:10.1177/1947601911407329 · Cited by 130
Costa, Â. M., Herrero, A., Fresno, M., Heymann, J. J., Alvarez, J. A., Cameselle‐Teijeiro, J., & García‐Rostán, G. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.03077.x · Cited by 143
Exon 15 BRAF Mutations Are Uncommon in Melanomas Arising in Nonsun-Exposed Sites
Cohen, Y., Rosenbaum, E., Begum, S., Goldenberg, D., Esche, C., Lavie, O., Sidransky, D., & Westra, W. H. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0562 · Cited by 134
“This hot spot was chosen because the reported BRAF-activating mutations in cutaneous nevi and cutaneous melanoma occur almost exclusively at this position (8, 10).”
Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade.
Collisson, E. A., De, A., Suzuki, H., Gambhir, S. S., & Kolodney, M. S. (2003) · PubMed · Cited by 129
Villaruz, L. C., Socinski, M. A., Abberbock, S., Berry, L. D., Johnson, B. E., Kwiatkowski, D. J., Iafrate, A. J., Varella‐Garcia, M., Franklin, W. A., Camidge, D. R., et al. (2015) · Cancer · doi:10.1002/cncr.29042 · Cited by 125
“61 Metastatic site in brain, n (%) Yes 1 (7) 22 (21) 39 (25) 14 (29) 12 (20) 52 (23) 5 (26) No 13 (93) 85 (79) 120 (75) 34 (71) 47 (80) 173 (77) 14 (74) Not reported 2 (13) 15 (12) 23 (13) 9 (16) 6 (9) 42 (16) 5 (21) Mid-P .”
InfluentialBRAF T1796A Transversion Mutation in Various Thyroid Neoplasms
Xing, M., Vasko, V. V., Tallini, G., Ларін, О. С., Wu, G., Udelsman, R., Ringel, M. D., Ladenson, P. W., & Sidransky, D. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031488 · Cited by 127
Garibyan, L., & Fisher, D. E. (2010) · Current Oncology Reports · doi:10.1007/s11912-010-0119-y · Cited by 166
“Up to 70% of human melanomas harbor mutations in BRAF [40], as do benign melanocytic nevi [41].”
BackgroundThe Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer
Wellbrock, C., & Arozarena, I. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00033 · Cited by 145
“In humans, BRAFV600E mutations are found in benign nevi (Pollock et al., 2003), clonal populations of senescent melanocytes (Gray-Schopfer et al., 2006).”
BackgroundBRAF mutations are detectable in conjunctival but not uveal melanomas
Spendlove, H. E., Damato, B. E., Humphreys, J., Barker, K. T., Hiscott, P. S., & Houlston, R. S. (2004) · Melanoma Research · doi:10.1097/00008390-200412000-00003 · Cited by 129
The Brn-2 Transcription Factor Links Activated BRAF to Melanoma Proliferation
GOODALL, J. C., Wellbrock, C., Dexter, T. J., Roberts, K., Marais, R., & Goding, C. R. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.7.2923-2931.2004 · Cited by 126
“5B) indicated that while expression of the wild-type BRAF protein had little effect on Brn-2 promoter activity, the promoter was strongly activated, up to 20-fold, by the most common BRAF mutant, V599E, which is found in the majority of melanomas and nevi (11, 26), weakly by the G463V mutant, and to an intermediate le…”
BackgroundInfluentialOvercoming resistance to BRAF inhibitors
Arozarena, I., & Wellbrock, C. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.06.09 · Cited by 123
“Intriguingly, this mutation is also found in up to 80% of human benign moles or nevi (6), which are considered senescent clones of melanocytes.”
BackgroundArmour, C. M., & Allanson, J. E. (2008) · Journal of Medical Genetics · doi:10.1136/jmg.2007.054460 · Cited by 122
Brn-2 Expression Controls Melanoma Proliferation and Is Directly Regulated by β-Catenin
Goodall, J., Martinozzi, S., Dexter, T. J., Champeval, D., Carreira, S., Larue, L., & Goding, C. R. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.7.2915-2922.2004 · Cited by 152
“Strikingly, expression of Brn-2 is not only upregulated by -catenin but is also elevated in response to mitogen-activated protein kinase signaling downstream from reporter tyrosine kinases (RTKs) and in particular downstream from BRAF (18), which is known to be activated by mutation in about 70% of melanomas and nevi…”
BackgroundCutaneous Melanoma: Prognostic Factors
Homsi, J., Kashani–Sabet, M., Messina, J. L., & DAUD, A. I. (2005) · Cancer Control · doi:10.1177/107327480501200403 · Cited by 123
Genomic profiling of malignant melanoma using tiling-resolution arrayCGH
Jönsson, G. B., Dahl, C., Staaf, J., Sandberg, T., Bendahl, P.-O., Ringnér, M., Guldberg, P., & Borg, Å. (2007) · Oncogene · doi:10.1038/sj.onc.1210252 · Cited by 132
“Known to be early events and present in benign nevi (Pollock et al., 2003), BRAF mutations may influence tumor progression and give rise to distinct gene expression signatures in melanoma cell lines (Pavey et al., 2004).”
BackgroundLin, J., Goto, Y., Murata, H., Sakaizawa, K., Uchiyama, A., Saida, T., & Takata, M. (2011) · British Journal of Cancer · doi:10.1038/sj.bjc.6606072 · Cited by 124
“Interestingly, the BRAFV600E mutation was also found in over 80% of melanocytic nevi, suggesting that mutational activation of the RAS/RAF/MEK/ERK pathway is a critical step in the initiation of melanocytic neoplasia (Pollock et al, 2003).”
Spitz melanoma is a distinct subset of spitzoid melanoma
Raghavan, S. S., Peternel, S., Mully, T. W., North, J. P., Pincus, L. B., LeBoit, P. E., McCalmont, T. H., Bastian, B. C., & Yeh, I. (2020) · Modern Pathology · doi:10.1038/s41379-019-0445-z · Cited by 130
“In contrast, the initiating mutations in common acquired nevi are much more homogeneous with over 80% harboring BRAF V600E mutations [17, 18].”
BackgroundTargeting the Mitogen-Activated Protein Kinase Pathway in the Treatment of Malignant Melanoma
Panka, D. J., Atkins, M. B., & Mier, J. W. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2539 · Cited by 120
“found in 80% of benign nevi (4) and are therefore by definition insufficient to cause the disease in the absence of other factors.”
BackgroundChapter 1 Genetic Models of Cancer in Zebrafish
Amatruda, J. F., & Patton, E. E. (2008) · International review of cytology · doi:10.1016/s1937-6448(08)01201-x · Cited by 127
Tsavachidou, D., Coleman, M. L., Athanasiadis, G., Li, S., Licht, J. D., Olson, M. F., & Weber, B. L. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1669 · Cited by 119
“The high incidence (up to 80%) in nevi and metastatic lesions (2, 7) but low frequency (10%) in early-stage melanomas suggest that BRAF mutations may correlate with progression rather than initiation of melanoma (3, 8).”
BackgroundBRAF Mutations in Conjunctival Melanoma
Gear, H. C., Williams, H. B., Kemp, E., & Roberts, F. (2004) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.04-0093 · Cited by 118
“Mutations have also been detected in up to 82% of cutaneous melanocytic nevi.(19) In contrast, this mutation appears to be absent from uveal melanomas, although it has been identified in choroidal melanoma cell lines.”
Polsky, D., & Cordon‐Cardo, C. (2003) · Oncogene · doi:10.1038/sj.onc.1206449 · Cited by 119
Melanocytic Nevi, Nevus Genes, and Melanoma Risk in a Large Case-Control Study in the United Kingdom
Newton‐Bishop, J., Chang, Y., Iles, M. M., Taylor, J., Bakker, E., Chan, M., Leake, S., Karpavicius, B., Haynes, S., Fitzgibbon, E., et al. (2010) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0233 · Cited by 132
BRAF, a target in melanoma: Implications for solid tumor drug development
Flaherty, K. T., & McArthur, G. A. (2010) · Cancer · doi:10.1002/cncr.25261 · Cited by 139
“tumors; but it was discovered subsequently that a very high proportion of benign nevi harbored BRAF mutations.(34,35) The correlation between BRAF mutation and ERK phosphorylation in clinical nevi or melanoma specimens was identified as quite weak.”
BackgroundOncogenic BRAFV600E inhibits BIM expression to promote melanoma cell survival
Cartlidge, R. A., Thomas, G. R., Cagnol, S., Jong, K. A., Molton, S. A., Finch, A. J., & McMahon, M. (2008) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2008.00491.x · Cited by 116
“Somatic activating mutations in BRAF are detected in approximately 85% of benign melanocytic nevi and 60–70% of all melanomas (Davies et al., 2002; Pollock et al.,2003).”
BackgroundGenomic alterations in spontaneous and carcinogen-induced murine melanoma cell lines
Melnikova, V. O., Bolshakov, S. V., Walker, C., & Ananthaswamy, H. N. (2004) · Oncogene · doi:10.1038/sj.onc.1207405 · Cited by 132
BRAF somatic mutations in malignant melanoma and melanocytic naevi
Thomas, N. E. (2006) · Melanoma Research · doi:10.1097/01.cmr.0000215035.38436.87 · Cited by 132
Metadata
- Authors
- Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., Salem, G., Pohida, T., Heenan, P., Duray, P., Kallioniemi, O., Hayward, N. K., Trent, J. M., & Meltzer, P. S.
- Affiliations
- National Institutes of Health (US)
- QIMR Berghofer Medical Research Institute (AU)
- The University of Western Australia (AU)
- Corresponding author
- Meltzer, Paul S.
- ORCID
- Venue
- Nature Genetics
- Published
- 2002-11-25
- Volume
- 33
- Issue
- 1
- Pages
- 19-20
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W1565041471
- Cited by
- 1,730
- References
- 4
- Citations by year
- 2026: 15 · 2025: 24 · 2024: 40 · 2023: 49 · 2022: 46 · 2021: 73 · 2020: 58 · 2019: 73 · 2018: 67 · 2017: 87 · 2016: 79 · 2015: 87 · 2014: 84 · 2013: 104 · 2012: 92
- FWCI
- 25.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Health Sciences › Medicine › Clinical Neurology › Neurofibromatosis and Schwannoma Cases
- Keywords
- BRAF mutation, melanocytic nevi, melanoma, melanoma metastasis, RAS/MAPK pathway, carcinogenesis
- MeSH terms
- Cell Transformation, Neoplastic, DNA Mutational Analysis, Gene Frequency, Humans, Melanoma, Nevus, Signal Transduction, Polymerase Chain Reaction, Genetic Predisposition to Disease, Mutation, Missense, Oncogene Proteins v-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.